Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.270
+0.010 (0.79%)
At close: May 27, 2025, 4:00 PM
1.260
-0.010 (-0.79%)
After-hours: May 27, 2025, 7:22 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Aclaris Therapeutics stock ranges from a low of $7.00 to a high of $16. The average analyst price target of $10 forecasts a 687.40% increase in the stock price over the next year.
Price Target: $10.00 (+687.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $16 | Strong Buy | Maintains | $20 → $16 | +1,159.84% | May 14, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $15 → $9 | Buy | Maintains | $15 → $9 | +608.66% | May 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 18, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $15 | Buy | Initiates | $15 | +1,081.10% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +1,474.80% | Dec 23, 2024 |
Financial Forecast
Revenue This Year
5.22M
from 18.72M
Decreased by -72.10%
Revenue Next Year
5.98M
from 5.22M
Increased by 14.59%
EPS This Year
-0.57
from -1.71
EPS Next Year
-0.64
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.1M | 9.3M | 9.3M | ||
| Avg | 5.2M | 6.0M | 7.9M | ||
| Low | 2.5M | 3.0M | 6.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -46.2% | 79.0% | 56.2% | ||
| Avg | -72.1% | 14.6% | 31.3% | ||
| Low | -86.4% | -41.8% | -0.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.56 | -0.54 | -0.61 | ||
| Avg | -0.57 | -0.64 | -0.71 | ||
| Low | -0.61 | -0.70 | -0.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.